DelveInsight’s “Heart Failure Pipeline Insight”report provides comprehensive insights about key companies and pipeline drugs in the Heart Failure pipeline landscapes. It comprises Heart Failure pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Heart Failure therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Heart Failure pipeline products.
Some of the key takeaways of the Heart Failure Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players Boehringer Ingelheim/Eli Lilly and Company, Merck Sharp & Dohme Corp/Bayer, AstraZeneca, such as, etc., are developing therapies for the treatment of Heart Failure.
-
Emerging therapies such as Empagliflozin, Vericiguat, AZD4831 & Dapagliflozin, Omecamtiv mecarbil, are expected to have a significant impact on the Heart Failure market in the coming years.
Get an overview of pipeline landscape @ Heart Failure Clinical Trials Analysis
Heart Failure Overview
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is corpulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle.
Heart Failure Emerging Drugs
-
Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
-
Vericiguat: Merck Sharp & Dohme Corp/Bayer
-
AZD4831 & Dapagliflozin: AstraZeneca
-
Omecamtiv mecarbil: Amgen, and others
For further information, refer to the detailed report @ Heart Failure Pipeline Therapeutics
Scope of Heart Failure Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Boehringer Ingelheim/Eli Lilly and Company, Merck Sharp & Dohme Corp/Bayer, AstraZeneca, and others.
-
Pipeline Therapies: Empagliflozin, Vericiguat, AZD4831 & Dapagliflozin, Omecamtiv mecarbil, and others.
Table of Contents
|
1 |
Heart Failure Report Introduction |
|
2 |
Heart Failure Executive Summary |
|
3 |
Heart Failure Overview |
|
4 |
Heart Failure- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Heart Failure Pipeline Therapeutics |
|
6 |
Heart Failure Late Stage Products (Phase II/III) |
|
7 |
Heart Failure Mid Stage Products (Phase II) |
|
8 |
Heart Failure Early Stage Products (Phase I) |
|
9 |
Heart Failure Preclinical Stage Products |
|
10 |
Heart Failure Therapeutics Assessment |
|
11 |
Heart Failure Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Heart Failure Key Companies |
|
14 |
Heart Failure Key Products |
|
15 |
Heart Failure Unmet Needs |
|
16 |
Heart Failure Market Drivers and Barriers |
|
17 |
Heart Failure Future Perspectives and Conclusion |
|
18 |
Heart Failure Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Heart Failure Drugs Pipeline Report.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/